


Mitochondrial Dysfunction and Oxidative Stress Play a Key Role in Age-Related Macular Degeneration¹

Valeda Offers a Brighter Horizon to Patients Suffering from Dry Age-Related Macular Degeneration

First Approved Treatment for Dry Age-Related Macular Degeneration (AMD) Using Photobiomodulation

Mitochondrial cytochrome C oxidase (CCO) is the primary photoacceptor target for photobiomodulation



Valeda uses light-emitting diodes (LEDs) to stimulate cellular function, leading to improved energy production within the mitochondria.

Valeda was designed for ease of use in the clinician's office

Under the clinician's supervision, trained staff are able to administer the Valeda treatment.

- Excellent safety profile
- Preserves future treatment options

Treatments are delivered in a series of 9 sessions per eye over a three-week period. Each treatment session lasts less than 5 minutes per eye.

Valeda is a platform with the potential to successfully treat a number of degenerative ocular diseases.



Indications for Use

The indicated use is for treatment of ocular damage and disease using photobiomodulation, including inhibition of inflammatory mediators, edema or drusen deposition; improvement of wound healing following ocular trauma or surgery, and increase in visual acuity and contrast sensitivity in patients with degenerative diseases such as dry age-related macular degeneration.

Wavelength 850²

Drives electron transfer (Cu_A), stimulates metabolic activity (ATP), and inhibits inflammation and cell death

Wavelength 660²

Promotes O₂ binding (Cu_B), stimulates metabolic activity (ATP), and inhibits inflammation and cell death

Wavelength 590^{3,4}

Inhibits VEGF expression and promotes nitric oxide generation



www.lumithera.com
Not for sale in the USA



Rx Only



LumiThera Corporation
19332 Powder Hill Place NE, Poulsbo,
Washington 98370 USA
www.lumithera.com



Emergo Europe
Prinsessegracht 20,
2514 AP The Hague
The Netherlands

Improves
Visual Acuity

Improves Contrast
Sensitivity


Reduces Central
Drusen Volume

¹ Jarrett et al., Mol Aspects Med.v33.2012. ² Wong-Riley et al., J Biol Chem.v280.2005. ³ McDaniel et al., Am Soc Laser Med Surg Mtg. 2006. ⁴ Ball et al., J Photochem Photobiol B Biol.v102.2012. ⁵ Munk et al., ARVO online planner: C0081. April 2018.

LIGHTSITE I STUDY


A Double-Masked, Randomized, Sham-Controlled Study with Photobiomodulation in Dry Age-Related Macular Degeneration Subjects⁵

AREDS Category Distribution at Baseline




Visual Improvement Demonstrated Immediately Following PBM and at Maintenance Therapy


Measurements at end of each Tx cycle – post-initial Tx and post 2nd Tx




Percent of PBM Tx Eyes That Achieved a 5+ Letter Gain



Contrast Sensitivity Significantly Improved at Each Time Point (18 cycles per degree)



Significant Reduction in Central Drusen Volume (CDV)



Pathology and Clinical Benefits as Seen in an Individual Patient

Central drusen volume reduction, 5+ letter gain and contrast sensitivity improvement

